CML is characterized by the BCR::ABL1 fusion gene, resulting in a constitutively active tyrosine kinase that is therapeutically targeted by small molecule inhibitors (García-Gutiérrez and Hernández-Boluda, 2019). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.